Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results-Reference-Cited by-同舟云学术

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results

Published:2018-09-09 Issue:11 Volume:93 Page:1301-1310
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Cortes Jorge E.¹,Douglas Smith B.²,Wang Eunice S.³,Merchant Akil⁴,Oehler Vivian G.⁵,Arellano Martha⁶,DeAngelo Daniel J.⁷,Pollyea Daniel A.⁸,Sekeres Mikkael A.⁹,Robak Tadeusz¹⁰^ORCID,Ma Weidong Wendy¹¹,Zeremski Mirjana¹¹,Naveed Shaik M.¹¹,Douglas Laird A.¹¹,O'Connell Ashleigh¹¹,Chan Geoffrey¹¹,Schroeder Mark A.¹²

Affiliation:

1. Department of Leukemia; University of Texas, MD Anderson Cancer Center; Houston Texas

2. Johns Hopkins Sidney Kimmel Comprehensive Cancer Center; Baltimore Maryland

3. Leukemia Service, Department of Medicine; Roswell Park Comprehensive Cancer Center; Buffalo New York

4. Department of Medicine, Keck School of Medicine; University of Southern California; Los Angeles California

5. Fred Hutchinson Cancer Research Center; Seattle Washington

6. Department of Hematology and Medical Oncology; Emory University School of Medicine; Atlanta Georgia

7. Dana-Farber Cancer Institute and Harvard Medical School; Boston Massachusetts

8. Division of Hematology; University of Colorado School of Medicine; Aurora Colorado

9. Leukemia Program; Cleveland Clinic; Cleveland Ohio

10. Department of Hematology; Medical University of Lodz; Lodz Poland

11. Pfizer Oncology; New York New York

12. Division of Oncology; Washington University School of Medicine; St Louis Missouri

Funder

Pfizer

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.25238/fullpdf

Reference57 articles.

1. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome;Daver;Leukemia.,2016

2. Phase III open-label randomized study of cytarabine in combination with amonafide l-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia;Stone;J Clin Oncol,2015

3. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML;Lancet;Blood.,2014

4. High-dose daunorubicin in older patients with acute myeloid leukemia;Löwenberg;N Engl J Med.,2009

5. Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes;Seymour;Crit Rev Oncol Hematol,2010

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia;Cell Death & Disease;2024-06-12

2. Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia;Cancers;2024-05-26

3. Glasdegib with intensive/nonintensive chemotherapy in Japanese patients with untreated acute myeloid leukemia or high‐risk myelodysplastic syndromes;Cancer Science;2024-02-07

4. Beyond the horizon: emerging therapeutic approaches in myelodysplastic neoplasms;Experimental Hematology;2024-02

5. Combating Acute Myeloid Leukemia via Sphingosine Kinase 1 Inhibitor-Nanomedicine Combination Therapy with Cytarabine or Venetoclax;Pharmaceutics;2024-01-31